Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
JD Health International, Inc. ( (HK:6618) ) has provided an announcement.
JD Health International Inc. has granted 536,489 share awards, equivalent to about 0.02% of its issued share capital as of the grant date, to employees of the group (excluding directors and senior management) under its post-IPO share award scheme, with no consideration payable by the grantees. The awards, priced with reference to HK$55.50 per share, will vest in tranches over periods ranging from 0.25 to 4 years and are governed by a strict clawback framework that allows the company to forfeit or cancel unvested and vested shares, and recover related proceeds, in cases such as termination for cause, criminal offences involving integrity or honesty, misconduct damaging the group, or in connection with financial restatements, reinforcing JD Health’s long-term incentive structure and risk management over employee compensation.
The most recent analyst rating on (HK:6618) stock is a Buy with a HK$70.00 price target. To see the full list of analyst forecasts on JD Health International, Inc. stock, see the HK:6618 Stock Forecast page.
More about JD Health International, Inc.
JD Health International Inc. is a Cayman Islands-incorporated company listed in Hong Kong that operates in the healthcare services and products sector under the broader JD.com ecosystem. It focuses on providing online and technology-enabled health services and solutions, leveraging digital platforms to serve consumers and partners in the healthcare market.
Average Trading Volume: 7,043,904
Technical Sentiment Signal: Buy
Current Market Cap: HK$181.3B
See more data about 6618 stock on TipRanks’ Stock Analysis page.